{"id":"W3182629320","doi":"10.1017/cjn.2019.163","title":"P.063 SUNFISH Part 1 results and Part 2 trial design in patients with type 2/3 spinal muscular atrophy (SMA) receiving risdiplam (RG7916)","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"SMN1; SMA*; Spinal muscular atrophy; Tolerability; Medicine; Adverse effect; Internal medicine; Placebo; Pharmacodynamics; Oncology; Pharmacokinetics; Pharmacology; Disease; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002159213,0.001544948,0.00185506,0.0002936042,0.0003351881,0.0008722221,0.0006172113,0.001677465,0.01731187],"category_scores_gemma":[0.001456132,0.0006385354,0.001636087,0.0002336501,0.0006627596,0.0009586886,0.0003207102,0.001724381,0.001691843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005867126,"about_ca_system_score_gemma":0.0009225339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003840864,"about_ca_topic_score_gemma":0.0009870473,"domain_scores_codex":[0.9992767,0.0004026247,0.00003623933,0.0001314807,0.00004346664,0.0001094921],"domain_scores_gemma":[0.9993845,0.0001685463,0.0001285185,0.00005210205,0.00005594374,0.0002102905],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9759572,0.004294793,0.001282524,0.0005433474,0.0007504215,0.00009338776,0.0000569715,0.0003078834,0.003632179,0.0001907437,0.002376766,0.01051372],"study_design_scores_gemma":[0.8847211,0.1077186,0.003937775,0.00004133791,0.0004566054,0.00007897108,0.00002466439,0.0005250804,0.0003722968,0.0002582903,0.001845262,0.00001999918],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9617727,0.004948744,0.00125036,0.001808564,0.0006447187,0.01416595,0.005842729,0.0002142047,0.009352072],"genre_scores_gemma":[0.9606827,0.001478531,0.002657107,0.001903853,0.0005411521,0.01997375,0.003416068,0.00006140925,0.009285619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01731187,"threshold_uncertainty_score":0.05791396,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03959955267806798,"score_gpt":0.2799191363844825,"score_spread":0.2403195837064145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}